BioAdvance
VC Fund
Philadelphia, United States
BioAdvance is a VC fund in Philadelphia focused on Biotechnology and Health Care. BioAdvance provides funding to startup life sciences companies in Southeastern Pennsylvania through its new $50 million Greenhouse Fund. They invest in therapeutics, devices, diagnostics and platform technologies focused on human health.Since its first investments in 2003, BioAdvance has become one of the nation's leading investorsproviding pre-seed and seed-stage funding. To date they have committed more than $40 million to more than 50 seed-stage companies and 17 pre-seed companies. Their portfolio companies are working to develop products to treat health problems including Alzheimer's disease, cancer, obesity, GI disorders, neurological and respiratory illnesses. BioAdvance was established with $33 million from the Commonwealth of Pennsylvania's share of tobacco settlement monies.
- Total investments:
- 125
- Last investment:
- Lead investor:
- 14%
- Fund size:
- $20M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BioAdvance invests in
Stages BioAdvance invests in
Countries BioAdvance invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $350k–$3M
- Series A
- $3M–$40M
Investment Focus
Industry
- Biotechnology 45 (36%)
- Health Care 35 (28%)
- Medical 23 (18%)
- Pharmaceutical 16 (13%)
- Therapeutics 8 (6%)
Stage
- Seed 39 (31%)
- Funding Round 21 (17%)
- Series A 17 (14%)
- Series B 8 (6%)
- Series C 3 (2%)
Country
- United States 59 (47%)
- Canada 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Shahram Hejazi
Partner
|
Partner | Total investments: 31 | Find email | |
Gregory Harriman
Partner and Chief Investment Officer
|
Partner and Chief Investment Officer | Total investments: 3 | Find email | |
Jeff Edelson
Entrepreneur in Residence / Scientific Liason
|
Entrepreneur in Residence / Scientific Liason | Total investments: 0 | Find email | |
Marnie McCoy
Program Director
|
Program Director | Total investments: 0 | Find email | |
Robert P. Driscoll
Director of Finance
|
Director of Finance | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Latus Bio
|
Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing. | $43M / Series A / May 04, 2026 | |
Overwatch Health
|
Overwatch Health offers an AI-assisted virtual rehab for cardiac and pulmonary patients. | Dec 19, 2024 | |
Palvella Therapeutics
|
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | Post-IPO Equity / Dec 13, 2024 | |
Tolerance Bio
|
Tolerance Bio is a biopharmaceutical company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases thymus. | $20.2M / Seed / Oct 15, 2024 | |
Vittoria Biotherapeutics
|
Vittoria Biotherapeutics develops gene-edited cell therapies. they provide next-generation, paradigm-shifting T-cell therapeutics that address unmet medical needs. Senza5 Technology from viTToria improves the efficacy, safety, and utility of cell-based treatments in preclinical settings. | $15M / Nov 13, 2023 | |
KayoThera
|
KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey. | $5.2M / Series A / Jul 19, 2023 | |
|
Palvella Therapeutics
|
Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | $37.7M / Series D / Jan 05, 2023 | |
Senzo
|
Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device. | $1.9M / Seed / Dec 12, 2022 | |
Innervace
|
Innervace is a developer of a regenerative therapy company designed to develop implantable tissue-engineered brain pathways for neurodegenerative disorders.The company is focused on the development and commercialization of anatomically inspired living scaffolds for brain pathway reconstruction, and its lead clinical product is a tissue-engineerednigrostriatal pathway that mimics the lost nigrostriatal pathway in patients with Parkinson's disease. This gives patients access to technology that specifically reconstructs brain pathways rather than just masking symptoms temporarily.Innervace was established in 2018 by in Philadelphia, Pennsylvania | $40M / Series A / Sep 08, 2022 | |
|
Senzo
|
Orphidia is developing a rapid blood diagnostic platform to simultaneously run common lab tests on a portable device. | $2M / Seed / Jul 21, 2022 | |
| See all 125 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does BioAdvance invest in?
BioAdvance invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Funding Round stage. Most of the 125 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BioAdvance's check size?
BioAdvance typically joins rounds of $350k–$3M at Seed and $3M–$40M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioAdvance participates in.
How do I contact BioAdvance?
Public channels for BioAdvance include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioAdvance?
The team at BioAdvance includes Shahram Hejazi (Partner), Gregory Harriman (Partner and Chief Investment Officer) and Jeff Edelson (Entrepreneur in Residence / Scientific Liason). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
